Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Octapharma factor VIII concentrates
- Development stage
- Unknown
- Lead developer
- Octapharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Octapharma factor VIII concentrates refer to a portfolio of Factor VIII (FVIII) replacement therapies developed by Octapharma AG for the treatment of haemophilia A. This group includes Nuwiq (simoctocog alfa), a fourth-generation recombinant human FVIII produced in a human cell line; Octanate, a plasma-derived FVIII concentrate; and Wilate, a plasma-derived concentrate containing both von Willebrand factor (VWF) and FVIII. These products function by replacing the deficient or absent clotting factor VIII in patients with congenital haemophilia A, thereby restoring the intrinsic pathway of the coagulation cascade and enabling the formation of stable blood clots. These concentrates have been evaluated in various clinical settings, including the Protect-NOW study, which documented their effectiveness and safety in previously untreated and minimally treated patients.
- Brand names
- NuwiqOctanateWilate
- Other names
- Octapharma FVIII concentrates
02
Targets
F10 (Factor Xa)BB-031 (Von Willebrand factor)PS (Phosphatidylserine)Coagulation Factor IXa
Beyond the preview
Go deeper on Octapharma factor VIII concentrates.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Octapharma factor VIII concentrates.